Introduction: Anaplastic thyroid cancer is a rare and fatal malignancy, associated with significant local tumour and often treatment related morbidity. We report our experience in treating this cancer over a 20-year period. Methods: A retrospective review of prospectively collected data from a single Australian Institution (Alfred Health Radiation Oncology) was carried out on patients referred with anaplastic thyroid carcinoma between 1992 and 2013. Results: Thirty patients (17 females and 13 males) were identified with a median age at presentation of 72 years. At presentation, six (20%), 14 (47%) and 10 (33%) patients had stage IVA, IVB and IVC disease respectively. Thirteen patients underwent radical surgical resection with five having microscopic residual (R1) and eight having macroscopic residual (R2) disease. Twentyeight patients were offered radiotherapy with 27 proceeding with treatment. Of those who received radiotherapy, three, six and 18 were treated with adjuvant, definitive and palliative intent respectively. Six patients had concomitant chemotherapy of which three received trimodality therapy. Only one patient experienced a grade 3 toxicity (oesophagitis). Median survival was 5.3 months and at last follow-up or time of death, 19 of 27 (70.4%) maintained loco-regional control. All patients who had R1 surgical resections and radiotherapy had loco-regional control. Seven of nine (77.8%) and 12 of 18 (66.7%) achieved loco-regional control after receiving definitive or palliative radiotherapy, respectively. Conclusions: Our study suggests that radiotherapy with or without surgery or chemotherapy is well-tolerated and results in durable loco-regional control in a high proportion of patients with anaplastic thyroid carcinoma.
Introduction
Anaplastic thyroid carcinoma (ATC) is a rare and rapidly fatal solid tumour, representing approximately 2% to 5% of all thyroid malignancies. 1, 2 The mean survival is six months or less and there are very few long-term survivors. 2 Reflecting this poor prognosis, the Union for
International Cancer Control (UICC) staging system classifies all ATC as stage IV independent of disease extent. 3 American Thyroid Association (ATA) guidelines recommend that patients with stage IVA and IVB ATC be considered for radical surgical resection if gross negative margins (R0/R1) can be achieved with minimal morbidity and should not be attempted if there is a high chance of an incomplete resection (R2). 4 It also advises against palliative debulking surgery. Only a small proportion of patients will, however, undergo surgery as, at diagnosis, the majority of patients will have extensive unresectable and/or metastatic disease. Additionally, a large proportion of patients will be elderly and hence often unsuitable surgical candidates due to their coexistent co-morbidities.
heterogeneity of ATC, these data will likely never be available. What is clear is that trimodality treatment is not without significant morbidity. This is important given the majority of patients are elderly and multimodality therapy is associated with only a modest survival benefit and patients will still inevitably die from ATC. 7 The policy at Alfred Health Radiation Oncology has evolved such that the aim of treatment is prevention of local morbidity, not only from local disease progression, but also from morbidity of treatment. This is a report of our experience in treating ATC over a 20-year period showing that good loco-regional control is achieved with local radiotherapy in this disease.
Methods
Alfred Health Radiation Oncology was established in November 1992 and is associated with The Alfred (a tertiary referral hospital in Victoria, Australia). Alfred Health Ethics Committee approval was obtained to analyse patients referred to our centre with ATC between November 1992 and July 2013. Patient data were retrieved from a prospectively collected database (Clinic Administrative System 'CAS' Mirrabooka Systems, Queensland Australia) and patient records. Study follow-up details were collected up to July 2015.
Data were analysed using Microsoft Access and Excel and SPSS software for Windows (IBM SPSS Statistics, Version 22, IBM Corp). Survival was defined from the date of diagnosis and actuarial results were calculated using the Kaplan-Meier method. Loco-regional control was defined as the absence of symptomatic, physical or radiological disease progression within the treated area of the head and neck.
Radiotherapy
Definitive/adjuvant treatment was recommended to patients with good performance status and either stage IVA/IVB disease in whom an aggressive approach to treatment was considered appropriate by the treating radiation oncologist, the patient and the referring clinicians. Palliative radiotherapy to the primary was considered in younger patients with metastatic disease (stage IVC) or elderly patients (>70 years) who were predicted to have sufficiently long life expectancy to derive benefit from radiotherapy taking into consideration their symptoms, tempo and extent of disease, performance status and co-morbidities. We thus included in this category asymptomatic patients with aggressive disease in whom the aim of palliation was the maintenance of their asymptomatic status until death, but in whom it was considered their survival might be prolonged beyond a few months. All other patients were recommended best supportive care.
The doses used for definitive or adjuvant radiotherapy were 50 Gy or greater, with or without concomitant chemotherapy, in either daily or bi-daily fractionation schedules. Although doses of 50 Gy were used in patients receiving palliative radiotherapy, these were patients noted above with anticipated longer survival. Patients with a poor performance status were generally treated with doses below 40 Gy, often with short course, hypofractionated dose schedules.
Treatment volumes for definitive/adjuvant radiotherapy were defined utilizing pre-and post-operative imaging, operative notes and histology reports. The high dose volume included the primary gross disease, and involved nodes or nodes at high risk of involvement. In postoperative patients, this volume also included the surgical thyroid bed with a 1-1.5 cm margin for microscopic disease. Lower dose volumes would cover the elective cervical nodal regions II through to VI and superior mediastinum, if these were not already covered in the high dose region. Palliative radiotherapy would generally include the gross disease with a 1.5-2 cm margin to account for microscopic disease, internal motion and setup error.
Chemotherapy
Chemotherapy usage and regimen was left to the individual medical oncologist's discretion. Neoadjuvant and adjuvant chemotherapy was not routinely used or recommended.
Follow-up
Patients were assessed on a two to six monthly basis, depending on their performance status and the time since treatment, with history and examination. Radiological investigations were not routinely performed, given the main aim of treatment was symptomatic control.
Results
Between November 1992 to July 2013, 30 patients with ATC were referred to Alfred Health Radiation Oncology. Table 1 details the baseline patient demographics. There were 17 females and 13 males (1.3:1). The median age at the time of presentation to our department was 72 years (45-92 years). Ten patients (33%) had distant metastatic disease at the time of referral (stage IVC) while the remaining 20 (67%) had loco-regionally confined disease.
The diagnosis of ATC was confirmed histologically in 28 patients. Two additional patients had rapidly progressive disease and, at the time of primary surgery, extensive locally infiltrating disease. In one, the biopsy revealed medullary carcinoma of the thyroid and in the other the pathologist could not conclusively determine whether the patient had ATC or metastatic disease (this patient had no other evidence of metastatic disease or any other known or identified primary malignancy).
These two patients died within seven and two months, respectively. On the basis of surgical findings and the clinical behaviour of their presentations, it was felt that these patients had disease more in keeping with ATC than anything else and were included in this cohort.
Twelve patients had surgical resections. Five had gross macroscopic resections with microscopic residual disease only (R1) while seven had subtotal resections (R2). Four patients proceeded to surgery after initial biopsy revealed well-differentiated thyroid carcinoma, as did one whose biopsy only confirmed the presence of malignancy. Five patients were assessed preoperatively as having resectable disease but found to have more extensive disease intraoperatively. In two patients, the reasons for proceeding to surgery could not be determined retrospectively. Two patients had palliative tracheostomies for compromised airway.
Radiotherapy was offered to 28 patients, with 27 patients proceeding with treatment. One patient declined treatment and died at seven weeks from upper airway obstruction. Radiotherapy was not recommended for two patients as their disease was too advanced at presentation. They died at 10 and 20 days, respectively.
Of the 27 patients who received radiotherapy, three, six and 18 were treated with adjuvant, definitive and palliative intent, respectively (Table 2) . No patients received neoadjuvant/adjuvant chemotherapy and only six received concomitant chemotherapy. Three were treated with trimodality therapy (two receiving twice daily fractionation schedules). Of the patients who had concomitant chemotherapy, three had weekly doxorubicin, two had cisplatin based regimen and one was unknown. Overall five patients received palliative chemotherapy; one had doxorubicin/vincristine/cisplatin, another cisplatin/doxorubicin and one had doxorubicin alone. In two patients, the chemotherapy used could not be determined.
Overall survival
At last follow-up, all except one patient had died. Overall median survival was 5.3 months (95% CI 1.6-9.0). The median survivals of patients treated with definitive and Radiotherapy in anaplastic thyroid cancer palliative intent were 11.8 months (95% CI 9.2-14.4) and 3.6 months (95% CI 2.8-4.3), respectively ( Fig. 1) . Five patients were longer term survivors (greater than 12 months), all of whom had loco-regional and symptomatic control at last follow-up or time of death. Four of the five patients were treated with definitive/adjuvant intent and only one received trimodality therapy; this patient was a 70-year-old who had exploratory surgery (R2) followed by definitive chemoradiotherapy (60.29 Gy in 40 fractions delivered twice daily). He died 70.5 months after his diagnosis from metastatic disease. It is important to note that in the last year of his life he was found to be aspirating, presumably as a consequence of radiotherapy. He was treated before Intensity Modulated Radiation Therapy (IMRT) was routinely used in our department. The longest survivor in our study cohort was a 64-year-old who underwent a gross complete (R1) resection followed by adjuvant hyperfractionated accelerated radiotherapy, 60 Gy in 40 fractions delivered twice daily, without concomitant chemotherapy. Seven months later he presented with histologically confirmed pulmonary metastatic disease and was then treated with Adriamycin chemotherapy and with ongoing stability of his metastatic disease had the pulmonary metastases resected. He died from an unrelated event with no evidence of further recurrence of his ATC approximately 157 months after his initial diagnosis and 150 months after his diagnosis of metastatic disease. The histopathology in both of these unusually long survivors has been reviewed and reconfirmed as being ATC.
Two other long-term survivors were treated with radical intent. A 76-year-old who had an R2 resection was treated with definitive radiotherapy (50 Gy in 25 fractions daily) and survived 33.7 months. The other patient was a 62-year-old who had an R1 resection and subsequent adjuvant radiotherapy (60 Gy in 30 fractions daily) and was still alive 27.3 months after his diagnosis. The fifth longer term survivor was a 78-year-old who was #, fraction; 2D-CRT, conformal radiotherapy (≤ 2 fields); 3D-CRT, 3 dimensional conformal radiotherapy (≥ 3 fields); bd, twice daily fractionation; CRT, chemoradiotherapy; ES, exploratory surgery; Gy, Grey; IMRT, intensity modulated radiotherapy; LRR, loco-regional recurrence; LRR, loco-regional recurrence; od, once daily fractionation; OS, overall survival; PCT, palliative chemotherapy; R1, gross macroscopic resection with microscopic residual disease; R2, subtotal resection with gross residual disease; RT, radiotherapy; S, Surgery.
treated with palliative radiotherapy alone to a dose of 45 Gy in 15 fractions delivered once daily. She died 18.5 months after her initial diagnosis from metastatic disease with no loco-regional symptomatic disease.
Loco-regional control
Nineteen patients (70.4%) who received radiotherapy achieved loco-regional control at last follow-up or time of death, with six (22.2%) having progressive loco-regional disease and the loco-regional disease status in two patients was unknown at the time of their death. All patients who had R1 resections and radiotherapy achieved loco-regional control. Six of seven patients (85.7%), who had subtotal resections (R2) followed by radiotherapy maintained loco-regional control. Eight of 15 (53.3%) patients who received radiotherapy but not surgery maintained loco-regional control, five (33.3%) had progressive disease and loco-regional status in two patients was unknown (Table 3) .
When grouped according to treatment intent, seven of nine (77.8%) and 12 of 18 (66.7%) patients treated with definitive and palliative radiotherapy, respectively, achieved loco-regional control (Table 3) .
Dose schedule and treatment technique
Fifteen and 10 patients received daily and twice daily fractionation schedules, respectively. The remaining two patients had radiotherapy delivered in three fractions per week ( Table 4 ). The median definitive dose was 60 Gy delivered in 30 daily fractions and 60.29 Gy in 40 bi-daily fractions. In comparison, the median palliative dose was 40 Gy in 15 daily fractions and 46 Gy in 29 bi-daily fractions.
Two patients received short course hypofractionated palliative radiotherapy, 18 Gy in three fractions and 20 Gy in five fractions, respectively. Both of these patients had extensive local disease at presentation and tracheostomies in situ when referred. However, in view of their otherwise good health, it was considered appropriate to offer palliative radiotherapy with the aim of providing some improvement in local comfort. A week after completion of treatment, the first patient was able to breathe independently of her tracheostomy. She died approximately two weeks later. The second patient achieved a very good reduction in tumour size and by the end of his treatment, was much more comfortable. Within a month, however, the tumour had regrown and with best symptomatic care he died approximately two weeks thereafter.
Of the 27 patients treated with radiotherapy, 10 were treated with intensity modulated radiotherapy (IMRT), 10 with 3-dimensional conformal radiotherapy (3D-CRT) and seven with two fields (2D-CRT).
Toxicities
Only one patient had documented acute toxicity of grade 3 or above. He was treated with concomitant chemoradiotherapy using a bi-daily fractionation schedule and developed grade 3 oesophagitis requiring a PEG tube insertion and enteral feeds. Otherwise, all other patients had grade 2 or less toxicities with the most common acute toxicities being oesophagitis and radiation dermatitis.
Discussion
To our knowledge, this is the largest Australian series on ATC with only one other published Australian series R1, gross macroscopic resection with microscopic residual disease; R2, subtotal resection with gross residual disease. reporting on 18 patients also treated over a 20-year period. 8 Our patient population had a median age of 72 years at presentation and a female preponderance, which is similar to the other Australian NSW study and other international series. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Patients treated with definitive radiotherapy received doses of 50 Gy and above, similar to the doses reported in the ATA guidelines. 4 In our series, patients treated with a definitive/adjuvant intent had a longer median overall survival (11.8 months) compared to patients treated with palliative intent (3.6 months). Our results emphasize the ATA guidelines that in appropriately selected patients with good ECOG performance status and either stage IVA or IVB disease, longer survivals with good loco-regional control can be achieved with aggressive multimodal treatment with tolerable toxicities.
In our institution, the most important aim in the treatment of ATC is to minimize tumour related morbidity, even in the metastatic setting. Optimal loco-regional control is paramount in achieving this as almost all patients with ATC will present with a rapidly enlarging neck mass, which often causes significant local morbidity such as dyspnoea (30-50%), dysphagia (15-43%), dysphonia (16-53%) and cervical pain (around 30%). 2, 21 In addition, despite rapid dissemination being common in ATC, the immediate cause of death in approximately 75% of patients is due to local invasion and obstruction of adjacent structures of the neck. 5, 22 This is extremely distressing for patients when death is from suffocation due to upper airway obstruction. Despite ATC being considered relatively radioresistant, 5 radiotherapy with or without surgery or chemotherapy appears to lead to good loco-regional control in a high proportion (70%) of patients. This control appears durable, all five longer term survivors maintaining loco-regional and symptomatic control to last follow up or time of death. Patients treated with palliative intent also achieved high rates of loco-regional control (66.7%), despite being treated to lower overall doses and more often with daily rather than twice daily fractionation. We acknowledge that in general, the palliative doses utilized were still overall higher (median palliative doses above 40 Gy) than doses used in palliation for other solid tumours and bi-daily treatments were sometimes employed. The higher palliative doses utilized, however, appear tolerable with no grade 3 or higher toxicities observed.
There was one longer term survivor who received palliative short course hypofractionated (45 Gy in 15 fractions) radiotherapy alone. She survived 18.5 months and died of metastatic disease having maintained Our findings contrast those in the other Australian series where it was reported that many patients died from uncontrolled loco-regional disease. 8 In that study, only 46% of patients who received radiotherapy achieved local disease control. This difference may be attributable to several factors. Firstly, the definitive/adjuvant and palliative radiotherapy doses utilized in our institution were overall higher. Multiple studies have suggested that higher radiation doses may be associated with better outcomes, with different dose thresholds being suggested including 30 Gy, 40 Gy and 45 Gy. 6 Secondly, some studies have suggested that more aggressive trimodality therapy is associated with better outcomes, albeit with additional toxicity/morbidity. Only one patient in the other Australian series received trimodality therapy, compared with three in our study. Thirdly, none of the patients in the other series compared with 10 in ours received hyperfractionated radiotherapy, which has been shown to improve local control. 24, 25 Furthermore, the majority of patients in the other Australian series were treated with parallel opposed fields whilst our study generally used more conformal radiotherapy delivery techniques, such as 3DCRT and IMRT, which enables dose escalation with minimal increase in treatment associated morbidity and this treatment technique is recommended in the ATA guidelines. 4, 15, 26, 27 Tables 5 and 6 summarize other recently published retrospective case series on ATC since 2010. The median overall survival in this study (5.3 months) is comparable to the other published series, which ranged from 3 to 8 months. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Mohebati et al. and Derbel et al. 9, 18 both had better median survivals of 8 months. A possible reason for this difference could be due to their population groups being younger (median ages of 60 and 65 years, respectively, versus 72 years). It also appears that in both studies, a higher proportion of patients had surgical resections (83% and 100% vs 50%), received chemotherapy (61% and 86% vs 33%) and in the series by Derbel et al. a greater proportion (87% vs 33%) underwent hyperfractionated radiotherapy treatment. Although ATA guidelines recommend an R0/R1 resection, in our series approximately 60% only had an R2 resection and none achieved an R0 resection. Our high rates of R2 resections appears to be consistent with other recently published international series where 50% or more had an R2 resection (Table 5 ). It appears from this that it is difficult to determine, preoperatively, patients who are likely to achieve an R0/R1 resection. The main reasons in our study that patients proceeded with surgery in the first instance were that either they were considered to have resectable disease preoperatively but found to have more extensive and infiltrative disease intraoperatively or they were not initially diagnosed with ATC. Our study does, however, suggest that patients achieved better loco-regional control despite having only an R2 resection when compared with patients who did not undergo surgery (86% versus 53%). This may be due to the fact that patients who are unsuitable for surgical resection often have more extensive/infiltrative disease and/or are older with likely other co-morbidities and/or have worse ECOG performance status. However, Lowe et al. 28 also found similar better survival in patients who underwent surgical resection even if only an R2 resection was achieved. Our study is limited by the inherent limitations of a retrospective review of the management of a rare malignancy. We also do not have a comparative arm to help assess for true treatment effectiveness. It is difficult to make direct comparisons with other retrospective series due to these reports having the same issues with heterogeneity in patients and treatments.
Although aggressive trimodality therapy has been associated with a modest survival benefit, overall treatment outcomes still remain dismal. This highlights the importance of rapid evaluation and establishment of treatment goals in a multidisciplinary team setting together with assessment of patient preferences. As we gain a better understanding of the molecular pathways that are altered in ATC, outcomes may further improve with more directed therapies. 29 In conclusion, our study suggests that radiotherapy can provide very good loco-regional control in patients with ATC, a disease often associated with significant local morbidity, in either the definitive or palliative setting. The dose and fractionation used depends mainly on patient factors and in patients with a good performance status with no evidence of metastatic disease, the use of more aggressive multimodality treatment appears to be beneficial, in line with the ATA recommendations.
